|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2007-11-30
|
|
pubmed:abstractText |
Angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) are frequently used for the treatment for glomerulonephritis and diabetic nephropathy because of their albuminuria- or proteinuria-reducing effects. To many patients who are nonresponsive to monotherapy with these agents, combination therapy appears to be a good treatment option. In the present study, we examined the effects of the addition of an ARB (losartan) followed by titration upon addition and at 3 and 6 months (n=14) and the addition of an ACE-I followed by titration upon addition and at 3 and 6 months (n=20) to the drug regimen treatment protocol in type 2 diabetic patients with nephropathy for whom more than 3-month administration of an ACE-I or the combination of an ACE-I plus a conventional antihypertensive was ineffective to achieve a blood pressure (BP) of 130/80 mmHg and to reduce urinary albumin to <30 mg/day. During the 12-month treatment, addition of losartan or addition of an ACE-I to the treatment protocol reduced systolic blood pressure (SBP) by 10% and 12%, diastolic blood pressure (DBP) by 7% and 4%, and urinary albumin excretion by 38% and 20% of the baseline value, respectively. However, the effects on both BP and urinary albumin were not significantly different between the two therapies. In conclusion, addition of losartan or an ACE-I to an ongoing treatment with an ACE-I, or addition of an ACE-I to ongoing treatment with a conventional antihypertensive were equally effective at reducing the urinary albumin excretion and BP, and provided renal protection in patients with type-2 diabetic nephropathy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0916-9636
|
|
pubmed:author |
pubmed-author:AbeHirohikoH,
pubmed-author:FujiwaraHisayoshiH,
pubmed-author:HieiKunihikoK,
pubmed-author:KakamiMasaoM,
pubmed-author:MinagawaTaroT,
pubmed-author:MinatoguchiShinyaS,
pubmed-author:MurataIchijiroI,
pubmed-author:NaganoToshihikoT,
pubmed-author:OhashiHiroshigeH,
pubmed-author:OkumaToshioT,
pubmed-author:OsumiYukioY,
pubmed-author:TakatsuHisatoH,
pubmed-author:TakayaTadatakeT,
pubmed-author:TanakaTsutomuT,
pubmed-author:TsukamotoTatsuoT,
pubmed-author:YokoyamaHitomiH
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
929-35
|
|
pubmed:meshHeading |
pubmed-meshheading:18049024-Adult,
pubmed-meshheading:18049024-Aged,
pubmed-meshheading:18049024-Albuminuria,
pubmed-meshheading:18049024-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:18049024-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:18049024-Blood Glucose,
pubmed-meshheading:18049024-Blood Pressure,
pubmed-meshheading:18049024-Blood Urea Nitrogen,
pubmed-meshheading:18049024-Creatinine,
pubmed-meshheading:18049024-Diabetes Mellitus, Type 2,
pubmed-meshheading:18049024-Diabetic Nephropathies,
pubmed-meshheading:18049024-Drug Therapy, Combination,
pubmed-meshheading:18049024-Female,
pubmed-meshheading:18049024-Hemoglobin A, Glycosylated,
pubmed-meshheading:18049024-Humans,
pubmed-meshheading:18049024-Losartan,
pubmed-meshheading:18049024-Male,
pubmed-meshheading:18049024-Middle Aged,
pubmed-meshheading:18049024-Treatment Failure,
pubmed-meshheading:18049024-Uric Acid
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy.
|
|
pubmed:affiliation |
Second Department of Internal Medicine, Gifu University School of Medicine, Japan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study
|
